Pharmacokinetic-Pharmacodynamic Modelling of Danofloxacin in Turkeys

Colibacillosis is a systemic disease responsible for important economic losses in poultry breeding; fluoroquinolones, including danofloxacin, are used to treat diseased animals. The purpose of the present study was to estimate pharmacokinetic–pharmacodynamic (PK-PD) surrogates for bacteriostasis, bactericidal activity and bacterial elimination against Escherichia coli O78/K80, using a PK-PD approach, for danofloxacin in turkeys after oral administration. Eight healthy turkeys, breed BUT 9, were included in a two-way crossover study. The drug was administered intravenously (i.v.) and orally at a dose rate of 6 mg/kg bw. The values of the elimination half-life and the total body clearance after i.v. administration were 8.64 ± 2.35 h and 586.76 ± 136.67 ml kg^-1h^-1, respectively. After oral administration, the values of the absolute bioavailability and the elimination half-life were 78.37± 17.35% and 9.74± 2.93 h, respectively. The minimum inhibitory concentration against the investigated strain in turkey serum was 0.25 μg/ml, four times higher than in broth. The lowest effective ex vivo AUC₂₄/MIC ratios required for bacteriostasis, bactericidal activity, and total killing of E. coliO78/K80 were 0.416 h, 1.9 h and 6.73 h, respectively. The oral dose of 6 mg/kg used in the present study could be interpreted as being sufficient to eliminate E. coli with an MIC 0.25 μ g/ml. However, considering the demand that antimicrobial resistance should be avoided by complete bacterial elimination, PK-PD considerations suggest that an even higher dose of 32 mg/kg per day or 0.7 mg/kcal per day should be evaluated in clinical trials.     

Pharmacokinetics of enrofloxacin and danofloxacin in premature calves

The aim of this study was to determine the pharmacokinetics/pharmacodynamics of enrofloxacin (ENR) and danofloxacin (DNX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. The study was performed on twenty‐four calves that were determined to be premature by anamnesis and general clinical examination. Premature calves were randomly divided into four groups (six premature calves/group) according to a parallel pharmacokinetic (PK) design as follows: ENR‐IV (10 mg/kg, IV), ENR‐IM (10 mg/kg, IM), DNX‐IV (8 mg/kg, IV), and DNX‐IM (8 mg/kg, IM). Plasma samples were collected for the determination of tested drugs by high‐pressure liquid chromatography with UV detector and analyzed by noncompartmental methods. Mean PK parameters of ENR and DNX following IV administration were as follows: elimination half‐life (t_1/2λz) 11.16 and 17.47 hr, area under the plasma concentration–time curve (AUC_0‐48) 139.75 and 38.90 hr*µg/ml, and volume of distribution at steady‐state 1.06 and 4.45 L/kg, respectively. Total body clearance of ENR and DNX was 0.07 and 0.18 L hr^?1 kg^?1, respectively. The PK parameters of ENR and DNX following IM injection were t_1/2λz 21.10 and 28.41 hr, AUC_0‐48 164.34 and 48.32 hr*µg/ml, respectively. The bioavailability (F) of ENR and DNX was determined to be 118% and 124%, respectively. The mean AUC_0‐48CPR/AUC_0‐48ENR ratio was 0.20 and 0.16 after IV and IM administration, respectively, in premature calves. The results showed that ENR (10 mg/kg) and DNX (8 mg/kg) following IV and IM administration produced sufficient plasma concentration for AUC_0‐24/minimum inhibitory concentration (MIC) and maximum concentration (C_max)/MIC ratios for susceptible bacteria, with the MIC₉₀ of 0.5 and 0.03 μg/ml, respectively. These findings may be helpful in planning the dosage regimen for ENR and DNX, but there is a need for further study in naturally infected premature calves.     

单诺沙星在蛋雏鸡体内的药物动力学及生物利用度的研究

选用 4～ 5周龄健康蛋雏鸡 12 5只 ,按 5 mg/kg的剂量进行静脉注射和内服单诺沙星的药动学研究及生物利用研究。高效液相色谱内标法测定血浆中药物浓度 ,MCPKP药动学程序处理药时数据。静脉注射和内服给药后血药浓度—时间数据分别符合无吸收因素二室开放式模型和一级吸收一室开放式模型。静脉注射给药的主要药动学参数为 :t1 /2α=0 .3313h、t1 /2β= 5 .994 0 h、Vd=7.5 2 4 6 L/kg、AU C=5 .6 916 μg/m l· h、CLB=0 .8935 L/kg· h。内服给药后主要药动学参数为 :t1 /2 Ka=0 .30 2 9h、t1 /2 K=6 .5 12 8h、tmax=1.2 10 0 h、Cmax=0 .5 15 9μg/m l、AU C=5 .132 9μg/ml· h。生物利用度为 90 .18%。     

Pharmacokinetics and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous,intramuscular, subcutaneous,and oral administrations

The aim of the present study was to determine the pharmacokinetics (PKs) and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations at a dose of 10 mg/kg. A total of eight clinically healthy chukar partridges weighing 480 ± 45 g were used for the investigation. The study was performed in a crossover design (2 × 2 × 2 × 2) with a 15‐day washout period between two administrations in four periods. The plasma concentrations of danofloxacin were determined using reversed‐phase high‐performance liquid chromatography. Noncompartmental PK parameters were also estimated. No local or systemic adverse drug effects were observed in any of the chukar partridges. The mean elimination half‐life ranged between 8.18 and 12.08 hr and differed statistically among administration routes. The mean peak plasma concentrations of danofloxacin following IM, SC, and PO administrations were 8.05, 9.58, and 3.39 μg/ml at 0.5, 1, and 4 hr, respectively. Following IM, SC, and PO administrations, the mean bioavailability was 86.33%, 134.40%, and 47.62%, respectively. The mean total clearance and volume of distribution at steady‐state following IV administration were 0.13 L hr^?1 kg^?1 and 0.96 L/kg, respectively. These data, including favorable PKs and the absence of adverse drug effects, suggest that danofloxacin is a useful antibiotic in chukar partridges.     

达氟沙星对猪胸膜肺炎放线杆菌的体外药效研究

为了解猪胸膜肺炎放线杆菌对达氟沙星的敏感性和达氟沙星的杀菌效果,收集和分离48株猪胸膜肺炎放线杆菌,采用微量肉汤稀释法和菌落计数法对体外药物敏感性试验和生长曲线、杀菌曲线进行了研究。猪胸膜肺炎放线杆菌对氨苄西林、磺胺异恶唑、头孢噻呋、大观霉素、黏菌素耐药率高,对阿莫西林/克拉维酸、复方新诺明、氟苯尼考、多西环素、庆大霉素、四环素、恩诺沙星、氧氟沙星、达氟沙星敏感。达氟沙星最小抑菌浓度(MIC)集中在0.0078μg/m L。达氟沙星浓度在MIC及以上时,随浓度升高,杀菌时间缩短,为典型的浓度依赖型抗生素。该试验结果可用于指导猪传染性胸膜肺炎的临床预防和治疗。     

甲磺酸丹诺沙星诱发中国仓鼠肺成纤维细胞（CHL）染色体畸变试验

采用体外培养中国仓鼠肺成纤维细胞（ＣＨＬ）对喹诺酮类经甲磺酸丹诺沙星的诱变性进行了检测，旨在对该药的遗传毒性作出评价，为安全和药提供数据。结果表明：加或不加代谢活化系统Ｓ９，甲磺诺沙星对ＣＨＬ细胞未见致染色体畸变作用。     

HPLC法测定鸡肉中达氟沙星残留量的测量不确定度评定

建立了高效液相色谱法（HPLC）测定鸡肉中达氟沙星残留量的测量不确定度评定的数学模型,对测量过程中的不确定度来源进行逐项分析和合成,得出了高效液相色谱法测定鸡肉中达氟沙星残留量的不确定度结果。     

达氟沙星对施氏鲟非特异性免疫功能的影响

采用经口灌服的方法,分别用20、50和100 mg.kg-1达氟沙星对施氏鲟连续给药20 d(每天1次),并于给药后第5、10、15和20天测定非特异性免疫指标.结果表明:达氟沙星对肝脏和血清溶菌酶含量有抑制作用;20和50 mg.kg-1组对血清中酚氧化酶活力先诱导后抑制,100 mg.kg-1组则始终表现抑制作用;该药使白细胞数量和细胞吞噬百分比降低,但对白细胞吞噬指数及肝脏和脾脏系数无显著影响(P>0.05).可见,达氟沙星使施氏鲟的非特异性免疫能力降低,但对免疫器官的生长指数没有明显的影响.     

单诺沙星对人工诱发鸡大肠肝菌病的药效试验

根据试管 2倍稀释法测定的单诺沙星及氯霉素对鸡大肠杆菌的最小抑菌浓度 ,对实验性大肠杆菌病鸡进行内服给药 (每隔 12h给药 1次 ,连续 3d)治疗试验。结果表明 ,单诺沙星及氯霉素对鸡大肠杆菌的最小抑菌浓度分别是 0 0 5及 1 6mg/L。单诺沙星以 5mg/kg、氯霉素以40mg/kg的剂量给鸡内服后 ,对大肠杆菌病的治愈率分别为 87 5%及 55 0 %。